9.1 Labeling of Dispensed Drugs

Two Layers of New York Labeling Law

New York regulates prescription labeling through two connected sources: Education Law § 6810(1), the base statute setting out the elements every dispensed label must carry, and 8 NYCRR § 63.12, a Board of Regents regulation (adopted under Education Law § 6830) that classifies those elements into a "critical" tier and an "important" tier and dictates how each must be displayed. On the MPJE, expect fact patterns testing whether a candidate knows which tier an element belongs to — and what happens when a label's formatting, not just its content, fails the rule.

Education Law § 6810(1): The Base Label

Every prescription drug dispensed in New York must carry a label affixed to the immediate container showing:

• The name and address of the pharmacy (the "owner of the establishment") where it was dispensed
• The date compounded (i.e., dispensed)
• The prescription number under which it is recorded in the pharmacist's files
• The name of the prescriber
• The name and address of the patient
• The directions for use given on the prescription

Notice what is not on this base list: the drug's own name and strength. A pharmacist who dispenses without all six § 6810(1) elements is violating the base statute — a separate violation from any § 63.12 formatting failure.

8 NYCRR § 63.12: Critical vs. Important Elements

Section 63.12 requires "standardized patient-centered data elements" on every dispensed label, taking most of § 6810(1)'s content, adding the drug's name and strength, and splitting the full set into two tiers with different display rules:

The rule exists so patients can find the three facts that matter most for safe self-administration — who takes it, how, and what it is — at a glance, without wading through pharmacy boilerplate. An MPJE answer stating "the pharmacy's address must be bolded" is wrong: bolding is reserved for the critical tier only, and bolding an important element actually violates the rule by undermining the critical-tier emphasis.

No Separate Beyond-Use Date Field

A frequent trap: candidates who have studied other states' MPJEs may expect a distinct "beyond-use date" (BUD) field the way some states require. New York's § 6810(1)/§ 63.12 framework does not enumerate a stand-alone beyond-use date among its required label elements — the "date of filling or refilling" serves as the patient-facing date reference. This does not relieve a pharmacist of the professional duty to assign an appropriate beyond-use date for compounded preparations under general USP compounding standards; it means the label-content statute itself has no separate BUD line item the way some other states' rules do.

Generic and Biologic Manufacturer Identification

8 NYCRR § 29.7(a)(6) — part of the Board of Regents' unprofessional-conduct rules — makes it a disciplinable offense to dispense a generic drug product or an interchangeable biological product without writing the name of the manufacturer (and the distributor, if different) on both the prescription and the label. This dual requirement is easy to test: a pharmacist who records the manufacturer only on the hard-copy prescription but leaves it off the vial label has still committed misconduct.

Special Case: Mifepristone and Misoprostol

New York law includes a narrow, privacy-driven exception: at the prescriber's request, the label for mifepristone or misoprostol may show the name or address of the prescribing practice instead of the individual prescriber's name. This accommodates reproductive-health providers who may have safety concerns about their personal name appearing on a patient's medication container.

Customized Patient Medication Packages

Multi-drug compliance packaging (e.g., blister "med-paks" for patients on complex regimens) is separately regulated under 8 NYCRR § 29.7(a)(15). These packages must be repackaged into moisture-proof, non-reclosable or evidence-of-tampering containers, must carry all § 6810(1) information plus the name, strength, physical description, and quantity of each medication, and must show an expiration date no longer than the shortest recommended expiration date of any ingredient. Controlled substances and therapeutically incompatible medications may not be combined in the same package, and the arrangement requires documented patient (or caregiver/prescriber) consent.

Common MPJE Traps

• Bolding or color-highlighting an important-tier element (e.g., the pharmacy's phone number) — the rule reserves emphasis for the critical tier only.
• Using an abbreviated sig ("Take 1 tab qd") on the label — § 63.12 requires directions in full sentences.
• Recording the generic manufacturer on the hard-copy Rx but omitting it from the label — § 29.7(a)(6) requires both.
• Assuming New York requires a distinct "beyond-use date" line — the statute's date field is the fill/refill date.